91 results
8-K
EX-99.1
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares
23 Apr 24
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
7:34am
. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.
IMPORTANT SAFETY INFORMATION … safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our
8-K
EX-99.1
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares
2 Apr 24
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
7:32am
pharmacokinetics (PK), safety, and efficacy of chronic SC administration of abiprubart and to provide optionality to evaluate abiprubart across a range …
The ongoing Phase 2 rheumatoid arthritis trial uses a randomized, double-blind, placebo-controlled design to evaluate PK, safety, and efficacy
8-K
EX-99.2
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares
2 Apr 24
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
7:32am
delays or difficulties with our clinical trials; potential inability to demonstrate safety or efficacy or otherwise producing negative, inconclusive … to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept
8-K
EX-99.1
2b9fud0a1r w4pdv
28 Feb 24
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
7:35am
8-K
EX-99.1
6od4i22hrl3a4 mih0p
4 Jan 24
Kiniksa Pharmaceuticals Provides Corporate Update
7:37am
8-K
EX-99.2
y9tcdvtcomnv27
4 Jan 24
Kiniksa Pharmaceuticals Provides Corporate Update
7:37am
8-K
EX-99.1
3ol27net
31 Oct 23
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
7:35am
8-K
EX-99.1
uk0c4vidj1fd
25 Jul 23
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
7:40am
8-K
EX-99.1
6m8n7s l13fcndso
2 May 23
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
7:34am
8-K
EX-99.1
85et lakecj
1 Nov 22
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:06am
8-K
EX-99.1
imiwgl7w
3 Aug 22
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:35am